The colon cancer prevention paradox

Patients at higher risk of colon cancer may get charged thousands of dollars for "surveillance" colonoscopies.

December 1, 2023 Check out STAT+

Sponsored By

Molly Ferguson for STAT STAT+ | Colon cancer prevention paradox: Higher-risk patients pay more for colonoscopy A "screening" colonoscopy has no copay. For those at higher risk for colorectal cancer, a "surveillance" colonoscopy can cost thousands. By Angus Chen STAT+ | Blood cancers may arise from CAR-T cells, but experts think only in very rare cases Thousands of patients have been treated with CAR-T therapy over the last decade; the agency is looking into 20 reports of secondary cancers. By Angus Chen STAT+ | AbbVie buys Immunogen, maker of targeted cancer drugs, for $10 billion Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company's recent trading price. By Damian Garde Susan Walsh/AP STAT+ | Biden invokes Defense Production Act to stem drug shortages Biden's plan to stem drug shortages involves using the Defense Production Act, a Cold War-era law, to bring drug making back to the U.S. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser